Rinvoq (upadacitinib) is a prescription drug that works to treat certain inflammatory conditions by decreasing the activity of immune system cells. Your response to this drug may vary based on ...

The third-place slot marked another return to form. Novo Nordisk’s Wegovy reclaimed the seat it held in December, backed by ...

Johnson & Johnson JNJ announced that the FDA has granted approval to its key drug, Tremfya, for its second inflammatory bowel disease (IBD) condition — moderately to severely active Crohn’s disease ...

The treatment has gained approval in the European Union (EU) for a range of conditions, including psoriatic arthritis, rheumatoid arthritis and Crohn's disease, but its use for GCA is still pending ...

Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options ...

With Keytruda, the best-selling drug in the world, facing the end of exclusivity in 2028, BioSpace looks at five drugs that ...

(American Journal of Gastroenterology) Real-world data confirmed the effectiveness of upadacitinib (Rinvoq) in Crohn's disease, with clinical remission achieved in 56% of patients at 6 months ...

Stock market sell-offs are often great opportunities to buy dividend stocks. That's because dividend yields move in the ...

RINVOQ is approved in the European Union (EU) for the treatment of adults with radiographic axial spondylarthritis, nonradiographic axial spondylarthritis, psoriatic arthritis, rheumatoid ...

You'll need passive income to live well in retirement, especially with Social Security's uncertain future. The Office of ...